Recent Articles from Investor Brand Network

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company targeting rare diseases, was spotlighted in a recent Zacks Small-Cap Research report that presented a favorable analysis, emphasizing the company’s advancements in vaccine and photodynamic therapy technologies.

Chinese battery electric vehicle (BEV) manufacturer BYD has once again outpaced Tesla in global electric vehicle sales. A recent financial report from the Shenzhen-based automaker revealed that BYD’s revenue surged by 29% in 2024, reaching an impressive $14.8 billion—eclipsing Tesla’s reported revenue of $13.5 billion for the same period.

Goldman Sachs increased its forecast for the price of gold indicating that it could reach $3,300 for every ounce by the close of this year. To back their revised prediction, the bank mentioned the increasing investment inflows into gold ETFs and the surging gold purchases of central banks around the world.

A recently published report indicates that the rate at which Medicare Advantage plans are growing is slowing down. The report was authored by HealthScape Advisors, a consulting company, together with Chartis, a healthcare advisory company.

Investor interest in firms extracting gold is ticking up as the precious metal’s price climbs to new highs . This renewed investor interest is stemming the recent tide in which money was flowing out of gold extraction companies.

The popularity of environmental, social, and governance (ESG) accountability has grown over the past couple of years as expectations of investors, consumer demand and regulatory scrutiny continues to increase.

The General Services Administration (GSA) is introducing a new artificial intelligence tool to assist its employees in their daily tasks.

Quantum BioPharma (NASDAQ: QNTM) reported its financial results for the fourth quarter and year ended Dec. 31, 2024, highlighting a strengthened balance sheet and strategic advances across its clinical programs. The company removed its Material Uncertainty Related to Going Concern, with $12.1 million in cash and a 36% reduction in net cash used for operations year over year. Operating expenses dropped over 32% to $16.1 million, while net loss narrowed 18% to $14.9 million. Quantum completed a clinical trial for its unbuzzd alcohol detox supplement, which showed a 40% faster reduction in blood alcohol concentration among participants. unbuzzd is now expanding through a master distribution agreement across Latin America and ongoing U.S. sales. The company also completed a Phase 1 trial of its multiple sclerosis treatment Lucid-MS, which was deemed safe and well-tolerated, with Phase 2 preparations underway. Other initiatives included a dual listing on Upstream, crypto treasury diversification, and the early development of rekvry, an alcohol misuse treatment for emergency settings.

Kairos Pharma (NYSE American: KAPA), a clinical-stage biopharmaceutical company, reported recent activity at major scientific gatherings and announced upcoming conference appearances. The company presented research on its GITR agonist KROS 101 at the Society for Immunotherapy of Cancer Spring Meeting on March 12, participated in BIO Europe from March 17 to 19, and will attend the Fierce Pharma Engage meeting in San Diego from April 29 to May 1. An abstract has also been accepted for presentation at the American Society of Clinical Oncology Annual Meeting in Chicago from May 20 to June 5. In addition, Maxim Group initiated research coverage of the company on March 27. CEO John Yu highlighted progress in Phase 2 trials for ENV105 and advancements in its KROS platform as signs of growing momentum in oncology innovation.

Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company advancing targeted immunotherapies, has entered into a securities purchase agreement with a single institutional investor for a registered direct offering of 3,325,000 shares of common stock at $0.65 per share, or pre-funded warrants in lieu of stock. Concurrently, the company will issue series G warrants to purchase up to 6,053,000 shares of common stock in a private placement. The total gross proceeds from both transactions are expected to be approximately $3.9 million before fees and expenses. Ladenburg Thalmann & Co. Inc. is acting as the exclusive placement agent. Calidi plans to use the proceeds to support working capital, general corporate purposes and advancement of its clinical programs.

Aditxt (NASDAQ: ADTX), a social innovation platform focused on accelerating health technologies, announced that its latest Aditxt Weekly Update will spotlight the recent acquisition of the CaSe Platform by its subsidiary, Pearsanta, Inc. The proprietary technology, based on adductomics, is engineered to detect early DNA changes that could lead to cancer and other diseases. The discussion will emphasize how the CaSe Platform supports Pearsanta’s mission of advancing early detection and prevention in oncology. Featured participants include Dr. Shahrokh Shabahang of Aditxt, Chris Mitton of Pearsanta, and Dr. Roger Giese, the platform’s co-inventor.

Knightscope (NASDAQ: KSCP), a developer of autonomous security robots and AI technologies, has entered into definitive agreements to sell 625,000 shares of common stock at $2.75 per share in a registered direct offering, expected to close on or about March 31, 2025. Gross proceeds are anticipated to total approximately $1.7 million before fees and expenses. H.C. Wainwright & Co. is acting as the exclusive placement agent. Knightscope plans to use the net proceeds for working capital and general corporate purposes.

The International Energy Agency (IEA) has reported that soaring electricity demand in 2024 led to increased power generation from both renewable energy sources and fossil fuels. The agency attributes this surge to record-breaking temperatures, which spiked air conditioning use and significantly raised global energy consumption.

Despite recent positive regulatory moves, the U.S. crypto industry may still be struggling with banking restrictions, according to industry insiders and experts.

Bitcoin miners are facing unprecedented challenges a year after the April 2024 halving event . The reduction in block rewards, stagnant Bitcoin prices, and rising operational costs have made profitability difficult. While some miners are shutting down, others are seeking innovative ways to stay afloat, such as repurposing mining heat and adopting sustainable energy solutions.

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company focused on therapies for neurodegenerative diseases, disclosed it received a noncompliance notice from the New York Stock Exchange on March 26, 2025, for falling short of continued listing standards under Section 802.01B. The notice stated that the company’s average global market capitalization over a 30-day period was approximately $37.9 million, while its stockholders’ equity as of Dec. 31, 2024, was $9.3 million—both below the $50 million threshold. Annovis will submit a compliance plan within 45 days and may remain listed during an 18-month cure period if the NYSE accepts the plan. Its stock will continue trading under the “ANVS” symbol with a “.BC” indicator reflecting noncompliance status.

G Mining Ventures Corp. (TSX: GMIN) (OTCQX: GMINF) reported strong fourth quarter and full-year 2024 results, highlighted by 40,147 ounces of gold production and net income of $47.6 million, or $0.21 per share, in its first full quarter of commercial output from the Tocantinzinho Mine. All-in sustaining costs for the quarter were $862 per ounce, with adjusted EBITDA of $77.9 million and free cash flow totaling $53 million. For the year, the company produced 63,566 ounces of gold, generating $62 million in net income and ending with $141.2 million in cash. GMIN also advanced its growth strategy with the acquisition of the Oko West project in Guyana and the Gurupi project in Brazil, positioning the company to exceed 500,000 ounces of annual gold production in the coming years.

Walking into Vibe Cultivators, an indoor marijuana farm in Sacramento, California, the first thing you notice is the strong, unmistakable smell of marijuana. The facility is filled with rows of plants stacked on two levels, bathed in artificial light.

California’s legal marijuana production rose by 11.8% in 2024, reaching 1.4 million pounds, according to a newly released report by the state’s Department of Cannabis Control (DCC).

Newton Golf (NASDAQ: NWTG) has completed a strategic rebranding to emphasize its commitment to innovation and align more closely with its mission of integrating advanced physics principles into golf-equipment design. The restructuring was not merely a change in name but a reflection of Newton Golf’s dedication to creating equipment that leverages the laws of physics to benefit golfers of all skill levels. Central to the company’s product lineup are the Newton Gravity Putters and Newton Motion Shafts. Renowned for their ultra-low balance point (“ULBP”) technology, the gravity putters promote a smoother, more controlled putting stroke. The innovation has garnered attention on professional tours, with several PGA champions integrating these putters into their games. Further, the motion shafts are designed to optimize energy transfer and enhance swing consistency, embodying Newton Golf’s commitment to precision engineering.

Platinum Group Metals (NYSE American: PLG) (TSX: PTM) is a frontrunner in lithium-sulfur battery innovation through its subsidiary, Lion Battery Technologies. By leveraging the unique properties of platinum and palladium, PLG is improving the efficiency and longevity of these batteries, which offer higher energy density, lower production costs, and environmental benefits compared to traditional lithium-ion batteries. With significant progress made in research, including testing at the Battery Innovation Center and securing key patents, PLG is positioning itself as a leader in next-generation energy storage. Aligned with global demand, PLG’s efforts position the company at the cutting-edge of this exciting technological frontier, ready to meet the energy challenges of tomorrow with powerful and sustainable solutions.

TransCode (NASDAQ: RNAZ), the oncology company committed to utilizing RNA therapeutics to more effectively treat cancer, has announced the closing of its sale of 10,250,000 shares of its common stock and warrants to purchase up to 10,250,000 shares of common stock priced at-the-market under Nasdaq rules, at a purchase price of $0.98 per share and accompanying warrant. The company secured approximately $10 million in gross proceeds from the offering. TransCode intends to use the proceeds primarily for product development activities, including one or more clinical trials with its lead therapeutic candidate, TTX-MC138, including related IND-enabling studies, as well as for working capital and other general corporate purposes. ThinkEquity acted as sole placement agent for the offering.

CISO Global (NASDAQ: CISO) announced it achieved unaudited positive Adjusted EBITDA in Q4 2024, marking a pivotal profitability milestone as it transitions from a cyber services company to a software-led, AI-powered cybersecurity enterprise. The company credits this progress to integrating 13 acquisitions, cutting costs through proprietary AI-driven security solutions and increasing high-margin software revenue. CISO expects at least $34 million in profitable services revenue and $5 million in software bookings for 2025, with software margins projected around 75%, supported by a robust sales pipeline and insurance partnerships.

Mullen Automotive (NASDAQ: MULN) reported record GAAP revenue of $3.18 million for the quarter ending March 31, 2025, as the electric vehicle maker intensifies its focus on cost reduction and commercial sales growth. The company will implement further staff reductions, lease eliminations and operational consolidations starting in April. Mullen is also prioritizing advancements in its battery cell and pack technologies while continuing to sell its Class 1 Mullen ONE cargo van and Class 3 Mullen THREE cab chassis truck, both fully certified for U.S. and California emissions standards. Deliveries of Bollinger’s Class 4 B4 Chassis Cab began in October.

Tonix Pharmaceuticals (NASDAQ: TNXP), announced that CEO Seth Lederman, M.D., will present a poster at the AAPM 2025 Annual Meeting, PainConnect, in Austin, Texas. The presentation is scheduled for April 5 at 11:45 a.m. CT during the event, which runs from April 3–6. The company develops and markets biopharmaceutical products and is advancing a pipeline of clinical-stage candidates.

Thumzup (NASDAQ: TZUP) a rising player in social media branding and programmatic marketing, has integrated artificial intelligence tools including GitHub Copilot and Claude AI by Anthropic into its software development process. The move aims to accelerate feature rollouts for the Thumzup app, which rewards users for promoting brands they enjoy. CEO Robert Steele said the tools are already driving faster development and reducing costs, positioning Thumzup to stay competitive while offering a cutting-edge user experience. The shift aligns with broader tech startup trends, as companies increasingly rely on AI to drive rapid growth with leaner teams.

Recent vehicle sales data from Europe reveals that Tesla, historically the world’s largest electric vehicle (EV) manufacturer, is losing ground to established automakers like Volkswagen and BMW Group. According to research platform JATO Dynamics, both BMW and Volkswagen sold more EVs than Tesla in the European market in February 2025, signaling trouble for the Texas-based automaker.

Scinai Immunotherapeutics (NASDAQ: SCNI), announced it has signed a binding option agreement to acquire Pincell srl, an Italian biotech developing PC111, a first-in-class antibody targeting severe skin blistering disorders. In tandem, Scinai’s Polish subsidiary submitted a €12 million non-dilutive grant application under the EU’s FENG program to fund the next development phase of PC111. The agreement positions Scinai to advance treatments for high-mortality conditions like pemphigus and Stevens-Johnson Syndrome without immunosuppression, with Pincell’s leadership expected to integrate into Scinai’s expanding European operations.

New research shows that firefighters diagnosed with gliomas tend to have a particular set of genetic mutations that aren’t so common in individuals engaged in other occupations. In the past, those specific gene mutations had been linked to haloalkane exposure. Haloalkanes are chemicals often used in fire extinguishers and fire retardants.

Cyberattacks are becoming more sophisticated, and fraudsters, criminals, and even state-backed hackers are increasingly using advanced techniques. Microsoft believes only AI can effectively counter these threats.

Oragenics (NYSE American: OGEN) reported significant strategic progress in Q1 2025 as it advances ONP-002, its intranasal concussion therapy, toward clinical Phase IIa trials in Australia. The company secured a partnership with BRAINBox Solutions to integrate diagnostic biomarkers with its treatment platform and raised approximately $5 million through a mix of equity and non-dilutive debt. Oragenics also finalized regulatory submissions and drug production, with first patient enrollment expected in Q2. With no FDA-approved treatments for concussion, ONP-002 is positioned as a potential first-in-class therapy addressing a major unmet need.

Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”), announced that its presentation for the Q1 Virtual Investor Summit has been made available for on-demand viewing on the event’s website ( https://ibn.fm/xPuSL ).

Foremost Clean Energy (NASDAQ: FMST) (CSE: FAT) has commenced its 2025 winter exploration program at the Hatchet Lake Uranium Project in Saskatchewan’s Athabasca Basin, aiming to drill 2,000 meters across eight holes targeting high-priority zones. The initiative builds on previous promising results from Denison Mines (NYSE American: DNN), Foremost’s largest shareholder, and focuses on uranium mineralization along key conductive trends. As uranium demand surges amid a global energy transition and supply shortfalls, Foremost is positioning itself to capitalize on the market’s growing need for new sources in stable jurisdictions.

Nightfood Holdings (OTCQB : NGTF) announced it is nearing the completion of two key acquisitions—Carryout Supplies (S W C Group) and Skytech Automated Solutions—as part of its strategy to lead innovation at the intersection of AI, robotics and hospitality. The acquisition of Carryout Supplies is expected to close imminently, followed closely by the acquisition of Skytech, which recently expanded its AI-powered Laundry Helper robot to a second location. These moves mark a significant milestone in Nightfood’s evolution from a specialty food company to a hospitality tech innovator, with further strategic expansion under active consideration.

SolarBank (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2), a premier developer and owner of renewable and clean energy projects, specializing in distributed and community solar initiatives throughout Canada and the U.S., is expanding its renewable energy footprint with the development of two new solar power projects in upstate New York. The company announced plans to build a 7.2 MW DC ground-mount solar project in Gainesville, known as the Jordan Rd project ( https://ibn.fm/dfntr ), and a 4.3 MW DC ground-mount solar project on Glen Rd ( https://ibn.fm/pu0xN ). Combined, these projects are expected to generate enough electricity to power approximately 1,350 homes.

Geopolitical tensions are accelerating the global shift from fossil fuels to renewable energy, International Renewable Energy Agency (IRENA) Director-General Francesco La Camera says. He argues that major geopolitical events, such as the Russia-Ukraine war or economic conflicts between global powers, could accelerate the transition to cleaner energy sources by disrupting traditional energy markets and forcing countries to rethink energy security strategies.

On March 21, Acting U.S. SEC Chair Mark T. Uyeda led the first session of the commission’s Cryptocurrency Task Force roundtable in Washington, D.C. During the event, he emphasized the need for the SEC to adopt formal rulemaking rather than relying on enforcement actions to regulate digital assets.

BMW has officially put the brakes on its plans to switch to solid-state batteries, citing high costs as the primary reason. While many automakers are racing to adopt this next-generation battery technology, BMW is taking a different approach. Instead of transitioning to solid-state batteries right away, the German carmaker is doubling down on improving lithium-ion batteries, which they believe still have untapped potential.

Quantum BioPharma (NASDAQ: QNTM) has appointed Terry Lynch to its board of directors, replacing Dr. Sanjiv Chopra, who will remain as an advisor. Lynch, a prominent advocate against micro-cap stock manipulation and CEO of Power Nickel (TSXV: PNPN), brings deep experience in biotech, mining finance and market reform. He is also a co-founder of Cardiol Therapeutics (NASDAQ: CRDL) and a consultant to bionxt solutions. As part of the appointment, Quantum granted Lynch 50,000 stock options at C$9.90 per share, expiring March 26, 2027.

New York’s governor, Kathy Hochul, has officially signed two measures that expand the state’s cannabis farmers’ market program. The measures allow licensed marijuana businesses to form broader partnerships and host independent “pop-up” functions.

Mrs. Lin, a 72-year-old Korean-American retiree, has lived in the same neighborhood for decades. She visits her longtime physician, a trusted figure in the community, for regular checkups. However, with many private-practice doctors retiring and younger physicians moving into large corporate healthcare settings, she now struggles to navigate an unfamiliar system that doesn’t always cater to her cultural and linguistic needs. Her story reflects a growing challenge for AAPI seniors across the country as the healthcare system struggles to keep pace with their specific needs.

Meta Platforms (NASDAQ: META) experienced a notable stock increase, closing up 3.9% on Monday, March 24, 2025. This surge follows reports of Meta’s discussions with India’s Reliance Industries to host Meta’s AI models in a forthcoming data center in Jamnagar, Gujarat, projected to be the world’s largest. The potential collaboration underscores Meta’s commitment to expanding its artificial intelligence footprint in the rapidly growing Indian market. Additionally, Meta reported a 22% revenue increase in 2024, reaching $164.5 billion, reflecting robust growth in its core social media business. ​

Alphabet (NASDAQ: GOOGL) (NASDAQ: GOOG) reported a 14% increase in revenue for 2024, reaching $350 billion. The growth was primarily driven by its core services, with Google Search generating $198.1 billion (56.6% of total revenue) and YouTube Ads contributing $36.1 billion (10.3%). Google Cloud also saw significant growth, bringing in $43.2 billion (12.4%). The U.S. market accounted for approximately half of Alphabet’s annual sales. ​

Amazon.com (NASDAQ: AMZN) experienced a stock uptick following analyst optimism regarding its artificial intelligence (AI) prospects after Nvidia’s recent GTC conference. Monness Crespi Hardt analyst Brian White highlighted Amazon Web Services’ (AWS) potential to benefit from the growing generative AI sector, reiterating a buy rating with a price target of $215. Despite a seven-week decline in Amazon’s stock amid a broader market downturn, analysts remain positive about the company’s long-term growth, particularly in AI.

Tesla (NASDAQ: TSLA) has achieved its fifth consecutive day of stock gains, closing at $288.14 on Tuesday, March 25, 2025. This 3.5% increase brings the stock up 28% over the past five days, reversing a two-month decline. The rally comes despite reports of falling sales in the European Union for the second consecutive month. Analysts attribute the surge to CEO Elon Musk’s encouragement for employees to retain their shares and confidence in Tesla’s self-driving and robotics technology. Key resistance levels to monitor include $300, $385, and $680, while support levels are identified at $217 and $155. ​

Social media branding and marketing innovator Thumzup (NASDAQ: TZUP) received a new pair of thumbs up votes recently when company insiders announced new open-market stock purchases of Thumzup shares, as well as ongoing share buyback activity under the company’s previously announced stock repurchase program.

Calidi Biotherapeutics (NYSE American: CLDI) announced promising early results from a phase 1 clinical trial evaluating its CLD-101 investigational agent, a neural stem cell-based oncolytic virotherapy, in collaboration with City of Hope. The trial, targeting recurrent high-grade glioma, is the first to assess multiple weekly intracerebral doses of CLD-101. Fourteen participants have been treated so far with no safety concerns, and the study is now enrolling patients into the highest dosing cohort. The trial has expanded to Northwestern University and Stanford University, and is supported by a $12 million grant from the California Institute for Regenerative Medicine. Calidi retains licensing rights to the technology, which was developed by City of Hope researchers.

Thumzup (NASDAQ: TZUP) announced the development of its patent-pending Lifestyle AI Agent Marketplace, a next-gen platform designed to deliver hyper-personalized experiences using specialized AI agents. The system will feature premium AI “swarms” that collaborate to create lifestyle plans in areas like travel, wellness, and entertainment, while offering real-time promotions to users from participating businesses. Thumzup also filed trademark applications for its AI-powered marketing tools, Gibberlink Advertising and GibberAds, both of which will enable dynamic engagement between users, influencers, and advertisers. Monetization strategies include influencer affiliate programs, business AI accounts, and transaction-based commissions.

The business world is constantly evolving, and the rise of Web3 is set to bring a revolutionary shift in how companies operate. Unlike traditional Web2 systems that rely on centralized platforms, Web3 leverages blockchain technology to create a decentralized, transparent, and user-controlled digital landscape. This transformation has the potential to reshape security, customer engagement, revenue models, and operational efficiency. Here’s why businesses should take Web3 seriously .

According to a recent study, individuals who have used classic psychedelics like LSD or psilocybin are less prone to episodes of bad headaches. These results, the study authors say, suggest classic psychedelics could in future be explored for their prophylactic potential against headache disorders.

Legislators in states across the country are working towards strictly regulating and/or banning intoxicating hemp products. This comes as products with THC derived from hemp continue to proliferate the legal markets following the passage of the 2018 Farm Bill.

Mobile payments are rapidly becoming one of the most common ways to buy and sell goods in the U.S. With a growing number of consumers preferring to shop online rather than in physical stores, mobile payment systems have become the go-to option for millions due to their convenience and ease of use.

Mullen Automotive (NASDAQ: MULN) announced record GAAP revenue of $3.18 million as of March 21, 2025, marking a 189% increase over its total 2024 revenue of $1.1 million. The surge reflects strong momentum in sales of its commercial EVs, including the Mullen ONE cargo van and Mullen THREE cab chassis truck, both of which are fully certified under U.S. emissions and safety standards. The company also highlighted progress from its Bollinger division, which began delivering its all-electric Class 4 B4 Chassis Cab truck in October. CEO David Michery stated the fiscal Q2 will close as the company’s strongest revenue quarter to date.

D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave”), a leader in quantum computing systems, software, and services, reported financial performance for the fourth quarter and full-year 2024, highlighting significant growth in bookings and a strengthened cash position. The company announced that bookings for the year reached $23.9 million, a 128% increase from 2023. Fourth-quarter bookings were totaled $18.3 million—more than a fivefold increase from Q4 2023 ( https://ibn.fm/T4BI5 ).

Silo Pharma (NASDAQ: SILO) announced the first dosing in a GLP-compliant toxicology and toxicokinetics study for its lead candidate, SPC-15, an intranasal treatment for post-traumatic stress disorder (PTSD). The study, part of an IND-enabling program, follows a pre-IND meeting with the FDA that aligned the company on the 505(b)(2) regulatory pathway, which may expedite approval and reduce development costs. SPC-15, a serotonin 5-HT4 receptor agonist developed in partnership with Columbia University, is intended to treat stress-related psychiatric disorders such as PTSD and anxiety.

Standard Lithium (NYSE American: SLI) announced a corporate update highlighting continued progress on its lithium development initiatives, including the start of a dual-track project finance and off-take process for its South West Arkansas Project. The process, launched in January, aims to support the project’s first phase, targeting 22,500 tonnes per year of battery-quality lithium carbonate production. In East Texas, the company’s joint venture with Equinor has expanded its mineral leasing program to 185,000 acres and identified a 67,000-acre project area centered on Franklin County, with the highest reported lithium brine grades in North America. A maiden inferred resource report is expected in Q3 2025. Standard Lithium continues to optimize its demonstration plant in Union County and views its East Texas brine assets as premier lithium resources in North America.

SolarBank (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2), a premier developer and owner of renewable and clean energy projects, specializing in distributed and community solar initiatives throughout Canada and the U.S., aims to deliver reliable clean and renewable power to keep people’s lights on and keep people connected by helping power data centers, as detailed by CEO Richard Lu during two separate podcasts recently: InvestorBrandNetwork’s Bell2Bell and Electrek’s Quick Charge .

Quantum BioPharma (NASDAQ: QNTM) announced that its licensee Celly Nutrition Corporation has introduced a new format of its unbuzzd beverage supplement—“On-the-Go Powder Stick Packs”—now sold in 8-pack display boxes. Designed for convenience and portability, the new packaging supports broader retail distribution in convenience, liquor, and drug stores across the United States. The product, which accelerates alcohol metabolism and reduces hangover symptoms, is also available online in 3-pack, 8-pack, and 18-pack formats. Quantum BioPharma holds a 25.71% stake in Celly Nutrition and receives up to 7% in royalties on sales of unbuzzd . The company also renewed a 45-day market awareness campaign with Life Water Media beginning March 26.

A recent poll conducted on behalf of a Utah medical marijuana advocacy group indicates that most Utah residents would support a ballot initiative to legalize recreational marijuana. The survey results show that 52% of voters favor such a measure—the same percentage that approved medical marijuana in the state in 2018.

Adageis, a leading healthcare technology company, is at the forefront of an industry shift as providers increasingly prioritize specific, high-impact artificial intelligence (“AI”) applications that enhance patient care and financial performance. The company was featured in a recent article that discussed its innovative AI-driven solutions through its ProActive Care Platform, which offers practical applications that directly impact revenue generation and patient care. Adageis’ AI solutions stand distinct in providing key competencies in several areas including risk identification and early intervention, revenue tracking and forecasting, clinical decision support, administrative task automation, and continuous patient monitoring. Adageis’ platform demonstrates how AI can deliver tangible results, helping providers navigate the challenges of value-based care with precision and efficiency.

MoneyShow, a premier producer of financial conferences for affluent investors, active traders, and financial advisors, has announced the return of Outlook 2025: Big Market Trends, Bold Investment Ideas . The two-day event, set to take place at the Hilton DFW Lakes in Dallas on Apr. 4-5, 2025, will provide actionable insights for navigating the opportunities and challenges of the new year. “Following the inauguration of President Trump, there has been increasing uncertainty and volatility in the markets. Investors are seeking answers about how important economic and political forces will influence their portfolios in 2025,” said MoneyShow’s Editor-in-Chief Mike Larson. “At this year’s Dallas conference, MoneyShow experts will provide actionable insights to help investors adapt their strategies, better understand emerging dynamics, identify the next major investment themes, and side-step unforeseen risks.”

SolarBank (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2) has closed a registered direct offering with a single institutional investor, securing approximately $8.5 million in gross proceeds. The investor, backed by a bulge bracket investment bank and active in the energy sector, purchased 2,394,367 common shares and an equal number of warrants at a combined price of $3.55 per share. The warrants are immediately exercisable at $4.45 per share and expire in five years, potentially generating up to an additional $10.65 million. SolarBank plans to use the proceeds to support battery energy storage system projects, a community solar project in New York, and for general working capital. A.G.P./Alliance Global Partners served as sole placement agent.

CNS Pharmaceuticals (NASDAQ: CNSP) announced results from its Phase 2 clinical trial evaluating Berubicin for recurrent or progressive Glioblastoma Multiforme (GBM). While the study did not meet its primary endpoint of statistically significant improvement in overall survival compared to standard-of-care Lomustine, Berubicin showed comparable results across key clinical outcomes, including in patients with poor tumor markers. Importantly, no cardiotoxicity was observed, a major concern with other anthracyclines, and the safety profile remained favorable. The company plans to continue analysis and explore further development of Berubicin and its pipeline candidate TPI 287 for CNS malignancies.

Annovis Bio (NYSE: ANVS), a clinical-stage drug platform company focused on neurodegenerative diseases, will present key data from its Phase 3 Parkinson’s and Phase 2/3 Alzheimer’s studies at the AD/PD 2025 conference in Vienna from April 1–5. Presentations will highlight buntanetap’s impact on cognition and motor function in early Parkinson’s patients, and its advantages for APOE4 carriers in Alzheimer’s disease. Annovis CEO Maria Maccecchini and SVP Cheng Fang will lead the sessions, with Maccecchini also joining a forum on novel therapeutic and biomarker strategies for PD and related disorders.

SKYX Platforms (NASDAQ: SKYX) reported a 48% year-over-year revenue increase, reaching $86.3 million in 2024, including a record $23.7 million in fourth-quarter sales. The company narrowed its net loss to $0.36 per share, improved gross profit to $24.6 million, and reduced general and administrative expenses by $5.7 million. SKYX ended the year with $15.5 million in cash and secured an additional $1.45 million in March 2025 funding. Management projects the company will achieve positive cash flow in the second half of 2025, driven by growing demand for its smart home plug & play technologies and strategic partnerships with major retailers and developers.

Nissan Motor’s ambitious $661 million investment in expanding electric vehicle (EV) production has been postponed until 2028. The Japanese automaker, in collaboration with South Korean battery manufacturer SK On, aims to secure a steady supply of EV batteries capable of powering at least one million midsize battery electric vehicles (BEVs).

Copper demand in America is projected to double over the coming decade, but the U.S. currently doesn’t have the needed production capacity to address this anticipated demand unless interventions are instituted to make it easier for new mines to start operating.

Scientists at The Pennsylvania State University have developed a groundbreaking method to transform out-of-use oil wells into large-scale clean energy batteries . This innovative approach repurposes depleted gas and oil wells to address environmental pollution while simultaneously enhancing clean energy adoption.

The U.S.SEC convened its crypto task force for the first time in a public setting on Friday, bringing together crypto experts to discuss how existing securities laws relate to digital assets. The discussion took place as the Trump administration pushes for a major shift in crypto regulation.

A recent study has revealed that four in every ten U.S. military veterans suffering from chronic pain use cannabis to manage their symptoms . Published in the journal Global Advances in Integrative Medicine and Health, the study found that 40% of veterans turn to marijuana to alleviate issues related to pain, sleep disturbances, and mobility challenges.

Scientists have for long been baffled as to why men have a higher likelihood of developing Parkinson’s disease when compared to women. A new study suggests a possible reason why this higher risk exists, and the culprit is a usually harmless protein within the brain.

Oppenheimer has revised its outlook for U.S. investment banking revenue in 2025, scrapping its previous forecast of a 32% increase. The financial firm now expects no growth in the sector, citing mounting concerns over tariffs and trade policy uncertainties. This decision reflects a growing sense of caution among Wall Street analysts who had been optimistic about a rebound in mergers and acquisitions (M&A) following Donald Trump’s return to the White House.

Hollywood creatives, including directors, actors, and writers, are speaking out against the easing of AI-related copyright laws. More than 420 industry professionals have signed an open letter asking the government to maintain strong copyright protections for AI. Leading the effort is actress Natasha Lyonne, joined by notable names like Mark Ruffalo, Bette Midler, Paul Simon, Aubrey Plaza, and Ava DuVernay.

Clene (NASDAQ: CLNN), a clinical-stage biopharmaceutical company advancing treatments for neurodegenerative diseases such as ALS and MS, will participate in the Jones Las Vegas Technology and Innovation Conference on April 8–9, 2025. Held at The Venetian Resort, the event will feature one-on-one meetings, panels, and networking with institutional investors. Clene CEO Rob Etherington will represent the company as it continues to highlight progress across its therapeutic pipeline. The conference is hosted by JonesTrading with marketing support from B2i Digital, Inc.

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company targeting rare diseases, has selected IBN to manage its corporate communications and investor outreach. Soligenix is advancing late-stage clinical programs through its oncology and inflammation-focused Specialized BioTherapeutics segment and its Public Health Solutions division, which develops vaccines for biothreats such as ricin, Ebola, and Marburg. With support from roughly $60 million in non-dilutive funding and a pipeline that includes multiple orphan and fast-track designations, the company is preparing for potential regulatory approvals. IBN will amplify Soligenix’s message through its expansive media and investor network.